{
    "clinical_study": {
        "@rank": "21563", 
        "acronym": "iTEPsein", 
        "brief_summary": {
            "textblock": "Main objective: To determine the optimal molar doses of the biospecific antibody TF2 and 68\n      Ga-IMP-288 and the optimal time for pretargeting for immuno-PET in patients with breast\n      carcinoma.\n\n      Secondary objectives: To study the sensitivity of the immuno-PET, compare its performance to\n      standard imaging methods, evaluate the safety of 150 MBq of 68 Ga-IMP-288; study the\n      development of immunization against TF2 or complex TF2-IMP-288;"
        }, 
        "brief_title": "ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "HER2 Negative Breast Carcinoma Expressing CEA", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Carcinoma", 
                "Recurrence"
            ]
        }, 
        "detailed_description": {
            "textblock": "\u2022 3 or 4  cohorts of 3 patients receiving different doses of TF2 IMP-288 with different\n      interval time. A last cohort (4 or 5 ): maximum of 21 additional  patients with the optimal\n      schedule.\n\n      Cohort I: TF2 120 nmol / 6 nmol IMP-288 / 24 hours\n\n      Cohort II: based on the results of the cohort I :\n\n        1. Good signal of the tumor but high background: increased interval time, 120 nmol TF2 / 6\n           nmol of IMP-288 / 30 hours\n\n        2. Low signal of the tumor: reduction of the interval time, 120 nmol TF2 / 6 nmol IMP-288\n           / 18 hours\n\n        3. Good signal of the tumor and good background signal  : dose reduction, 60 nmol TF2 /\n           3nmol IMP- 288 / 24 hours\n\n           Cohort III: based on results of cohort II:\n\n           - Good signal of the tumor : dose reduction, 102 nmol TF2 / 3 nmol IMP-288 / 30 h\n\n           Cohort IV : (optional) : based on results of cohort III\n\n             -  A last Cohort (IV or V) : 21 patients with the optimal schedule of injection\n\n             -  In the four weeks prior to the immuno-PET:\n\n                  -  Clinical examination,\n\n                  -  CEA and CA15-3,\n\n                  -  thoraco abdominal pelvic scan, bone scan, FDG-PET,\n\n                  -  immunohistochemistry ACE on the tumor if possible,\n\n                  -  Anti-Antibodies if the patient has already received MAb,\n\n                  -  pregnancy test within 2 days prior to immuno-PET,\n\n                  -  (creatinine > 2.5 normal) D0: Injection of TF2 D1 to D4: injection of 68\n                     Ga-IMP-288 (depending of the cohort) D0 to D4 : pharmacokinetics, imaging\n\n           Evaluation at 1 month of Immuno-PET:\n\n             -  Assessment of the clinical oncologist and - histological biopsy and / or surgery\n                performed according to the results of imaging and assessment of the potential\n                clinical impact\n\n           Evaluation at 3 and 6 months of immuno-PET:\n\n           based on the results of immuno-PET, evaluation and therapeutic decision of the\n           oncologist,\n\n           - Imaging (ultrasound, bone scintigraphy, CT or PET FDG),\n\n           - markers\n\n           -  Anti-Antibody Search\n\n           Inclusion criteria:\n\n           \u2022 Breast carcinoma, HER2 + (Dako) and HER2 + (fish) metastatic at least after treatment\n           according to the current consensus\n\n           \u2022 \u2265 18 years\n\n           \u2022 Negative pregnancy test for women of childbearing age. Women of childbearing age\n           should take effective contraception continuously for 3 months.\n\n           \u2022 Karnofsky \u2265 70 or ECOG 0-1\n\n           \u2022 Life expectancy of at least 6 months\n\n           \u2022 ACE of the tumor by immunohistochemistry or positive plasma CEA \u2265 10 ng / mL\n\n           \u2022 At least one measurable lesion on CT\n\n             -  creatinine > 2.5\n\n             -  Informed consent signed\n\n             -  Social insurance\n\n           Exclusion criteria:\n\n             -  Pregnancy or breastfeeding\n\n             -  Serious illness or co-morbidity risk assessed\n\n             -  History of cancer within 5 years except skin cancer other than melanoma or\n                carcinoma in situ of the cervix\n\n             -  Presence of anti-antibodies in patients who have previously received antibodies\n\n             -  Known hypersensitivity to antibodies or proteins\n\n             -  intellectual disability to sign the informed consent\n\n             -  diabetes\n\n             -  Persons protected by law"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Breast carcinoma, HER2 + (Dako) and HER2 + (fish) metastatic at least after treatment\n             with current consensus\n\n          -  \u2265 18 years\n\n          -  Negative pregnancy test for women of childbearing age. Women of childbearing age\n             should take effective contraception continuously for 3 months.\n\n          -  Karnofsky \u2265 70 or ECOG 0-1\n\n          -  Life expectancy of at least 6 months\n\n          -  ACE of the tumor by immunohistochemistry or positive plasma CEA \u2265 10 ng / mL\n\n          -  At least one measurable lesion on CT\n\n          -  creatinine < 2.5\n\n          -  Informed consent signed\n\n          -  Social insurance\n\n        Exclusion Criteria:\n\n          -  Pregnancy or breastfeeding\n\n               -  Serious illness or co-morbidity risk assessed\n\n               -  History of cancer within 5 years except skin cancer other than melanoma or\n                  carcinoma in situ of the cervix\n\n               -  Presence of anti-antibodies in patients who have previously received antibodies\n\n               -  Known hypersensitivity to antibodies or proteins\n\n               -  intellectual disability to sign the informed consent\n\n               -  diabetes\n\n               -  Persons protected by law"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01730612", 
            "org_study_id": "BRD 10/4-O"
        }, 
        "intervention": {
            "description": "ImmunoTEP", 
            "intervention_name": "TF2 - 68 Ga-IMP-288:", 
            "intervention_type": "Drug", 
            "other_name": [
                "TF2: trivalent recombinant humanized antibody recognizing the ACE and the peptide histamine-succinyl-glycine IMP-288 (HSG)", 
                "68 Ga-IMP-288: di-HSG peptide-DOTA-labeled with Gallium 68"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Bispecific"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ImmunoTEP", 
            "HER2 negative", 
            "Breast Cancer"
        ], 
        "lastchanged_date": "November 22, 2013", 
        "location": [
            {
                "contact": {
                    "email": "francoise.bodere@chu-nantes.fr", 
                    "last_name": "Fran\u00e7oise Bodere, Phd, MD"
                }, 
                "contact_backup": {
                    "email": "evelyne.cerato@chu-nantes.fr", 
                    "last_name": "Evelyne Scotet-c\u00e9rato, PhD", 
                    "phone": "00 32 2 53 48 28 40"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "Hospital"
                }, 
                "investigator": {
                    "last_name": "Francoise Bodere, PhD, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Rousseau Caroline <Caroline.Rousseau@ico.unicancer.fr>", 
                    "last_name": "Caroline rousseau, Phd? MD", 
                    "phone": "0032 240679931"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint Herblain", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "Institut de Canc\u00e9rologie de l'Ouest"
                }, 
                "investigator": {
                    "last_name": "Caroline Rousseau, PhD, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "official_title": "Pilot Study for Optimization of Immuno-PET Pretargeted With Anti-CEA Bispecific Antibody X Anti-HSG TF2 and the Peptide IMP-288 Radiolabeled With Gallium-68 -Pharmacokinetic and Imaging for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA", 
        "other_outcome": [
            {
                "measure": "\u2022 To assess the tolerance of 150 MBq of 68 Ga-IMP-288", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "To search for the development of immunization with TF2 and the complex TF2-IMP-288: ELISA", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "overall_contact": {
            "email": "francoise.bodere@chu-nantes.fr", 
            "last_name": "Fran\u00e7oise Bodere, PhD, MD", 
            "phone": "00 32 2 40 08 4136"
        }, 
        "overall_contact_backup": {
            "email": "evelyne.cerato@chu-nantes.fr", 
            "last_name": "Evelyne Scotet-C\u00e9rato, PhD", 
            "phone": "0032 253482840"
        }, 
        "overall_official": {
            "affiliation": "Nantes Hospital", 
            "last_name": "francoise Bodere, PhD, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France : ANSM", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pk blood after injections of TF2 and 68 Ga-IMP-288 and PET imaging semi-quantification with 60 to 120 minutes after injection of 68 Ga-IMP-288", 
            "measure": "evaluation of the tumor targeting (no Unit) and signal / noise ratio (no unit) by the immunoTEP with TF2 and 68-Ga-IMP-288", 
            "safety_issue": "No", 
            "time_frame": "One week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01730612"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "sensitivity of the immuno-PET and compare its performance to standard imaging methods, pathological data if available data or imaging follow-up of at least 6 months by RECIST and EORTC", 
            "measure": "Sensibility,  tolerance", 
            "safety_issue": "No", 
            "time_frame": "6 months after immunoTEP"
        }, 
        "source": "Nantes University Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale, France", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Immunomedics, Inc.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Nantes University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}